시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 리포솜 약물 전달 기기 시장 보고서(2025년)
Liposomal Drug Delivery Devices Global Market Report 2025
상품코드 : 1675944
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,514,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,416,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,318,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

리포솜 약물 전달 기기 시장 규모는 향후 몇 년동안 빠르게 성장할 것으로 예상되며, 2029년까지 12.4%의 연평균 복합 성장률(CAGR)로 86억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 표적 치료의 확대, 임상 검증 및 임상시험, 맞춤 의료의 중요성, 병용 요법의 개발, 규제 환경의 변화에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 생체적합성 리포솜 소재, 전달 시스템 혁신, 암 분야 적용, 병용요법, 리포솜 제제 맞춤화 등이 있습니다.

세계 암 환자 수 증가는 예측 기간 동안 리포솜 약물 전달 기기 시장의 성장을 견인할 것으로 예상됩니다. 리포솜 약물 전달 시스템은 방사선 요법, 화학 요법, 외과적 절제술을 포함한 암 치료의 표적 치료법으로 채택되고 있습니다. 예를 들어, 영국에 기반을 둔 암 자선단체인 맥밀란 암 지원(Macmillan Cancer Support)이 2022년 6월에 발표한 자료에 따르면, 암 환자 수는 2022년에 300만 명에 달하고, 영국에서는 2025년까지 약 350만 명, 2030년까지 400만 명으로 증가할 것으로 예측했습니다. 이처럼 전 세계 암 발병률 증가는 향후 몇 년동안 리포솜 약물 전달 기기에 대한 수요를 증가시킬 것으로 예측됩니다.

헬스케어 지출 증가는 향후 리포솜 약물 전달 기기 시장의 성장을 가속화할 것으로 예상됩니다. 이러한 의료비 지출 증가는 만성질환의 확산, 의료기술의 발전, 약값 상승, 소비자 기대치, 보험료 등 여러 가지 상호 연관된 요인에 기인합니다. 헬스케어 지출에는 리포솜 약물 전달 장치와 관련된 비용을 포함하여 광범위한 의료 및 헬스케어 관련 비용이 포함됩니다. 이러한 지출은 리포솜 약물 전달 시스템과 같은 의료 기술 및 기기의 연구 개발, 제조, 유통, 이용 등 헬스케어의 다양한 측면을 포괄합니다. 예를 들어, 미국 컨설팅 회사인 피터 G 재단이 2022년 7월에 발표한 보고서에 따르면, 공공 및 민간 의료비 지출은 2022년 4조 4,000억 달러(1인당 1만 3,413달러)에서 2031년 7조 2,000억 달러(1인당 2만 425달러)로 증가할 것으로 예측했습니다. GDP 대비 국민의료비(NHE)는 의료비가 경제 성장률보다 빠른 속도로 증가함에 따라 2022년 17.4%에서 2031년 약 20%까지 증가할 것으로 예상됩니다. 따라서 의료비 지출 증가가 리포솜 약물 전달 기기 시장의 성장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

LSH
영문 목차

영문목차

Liposomal drug delivery devices are microscopic colloidal spheres utilized to transport drug molecules to specific action sites.

Primary types encompass liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Liposomal doxorubicin, a chemotherapy drug under the anthracycline category, encapsulated within a liposome, inhibits cancer cell growth by blocking the enzyme topoisomerase. These devices find applications in treating fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy, utilized in hospitals, diagnostic centers, ambulatory surgery centers/clinics, and similar medical settings.

The liposomal drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides liposomal drug delivery devices market statistics, including liposomal drug delivery devices industry global market size, regional shares, competitors with a liposomal drug delivery devices market share, detailed liposomal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal drug delivery devices industry. This liposomal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liposomal drug delivery devices market size has grown rapidly in recent years. It will grow from $4.89 billion in 2024 to $5.38 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to drug delivery advancements, biomedical research, clinical validation, therapeutic applications, and biocompatibility enhancements.

The liposomal drug delivery devices market size is expected to see rapid growth in the next few years. It will grow to $8.61 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to targeted therapies expansion, clinical validation and trials, personalized medicine emphasis, combination therapies development, regulatory landscape changes. Major trends in the forecast period include biocompatible liposomal materials, innovations in delivery systems, application in oncology, combination therapies, customized liposome formulations.

The increasing number of cancer cases worldwide is expected to drive the growth of the liposomal drug delivery devices market during the forecast period. Liposomal drug delivery systems are employed as targeted therapies for cancer treatments, including radiation therapy, chemotherapy, and surgical resection. For instance, data published by Macmillan Cancer Support, a UK-based cancer charity, in June 2022, indicated that the number of individuals living with cancer reached 3 million in 2022 and is projected to rise to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Thus, the global increase in cancer incidence is anticipated to enhance the demand for liposomal drug delivery devices in the coming years.

Rising healthcare expenditure is expected to accelerate the growth of the liposomal drug delivery devices market in the future. This increase in healthcare spending can be attributed to several interconnected factors, including the growing prevalence of chronic diseases, advancements in medical technology, rising drug prices, consumer expectations, and insurance costs. Healthcare expenditure includes a wide range of medical and healthcare-related costs, encompassing expenses associated with liposomal drug delivery devices. These expenditures cover various facets of healthcare, including the research, development, manufacturing, distribution, and utilization of medical technologies and devices like liposomal drug delivery systems. For example, a report from the Peter G Foundation, a US-based consulting firm, in July 2022, projected that both public and private healthcare spending would rise from $4.4 trillion, or $13,413 per person, in 2022 to $7.2 trillion, or $20,425 per person, by 2031. In relation to GDP, National Healthcare Expenditure (NHE) is expected to increase from 17.4% in 2022 to approximately 20% by 2031, as healthcare costs escalate faster than economic growth. Therefore, the rising healthcare expenditure is driving the growth of the liposomal drug delivery devices market.

Numerous large companies are implementing various strategic initiatives, including new product development, which is expected to become a significant trend in the liposomal drug delivery devices market. These companies are collaborating to create liposomal drug delivery systems to enhance their product portfolios and expand their global operations. For example, in May 2024, Insmed, Inc., a US-based biotech firm, announced data from the ARISE study regarding ARIKAYCE (amikacin liposome inhalation suspension). Patients treated with ARIKAYCE demonstrated better outcomes than those receiving the comparator arm (a macrolide-based multi-drug regimen), as measured by the QOL-B instrument, with 43.8% of patients showing an improvement in their QOL-B respiratory score.

Key players in the liposomal drug delivery market are launching innovative products like liposomal nanostructures to gain a competitive advantage. Researchers have been focused on developing these nanostructures to enhance patient compliance by allowing for less frequent dosing while maintaining effectiveness. For instance, in February 2022, the National Center for Biotechnology Information reported that several commercial nano-liposomal products, such as Onivyde, Vyxeos, and Marqibo, have been approved and are currently utilized. These medications are specifically used in cancer treatment for certain types of leukemia or solid tumors, playing a vital role in oncology by providing therapeutic options for cancers that may resist conventional chemotherapy or necessitate liposomal drug delivery.

Leading companies in the liposomal drug delivery market are introducing groundbreaking products such as hydrochloride liposome injection to establish a competitive edge. Researchers are focused on creating liposomal nanostructures that improve patient compliance by enabling less frequent dosing while ensuring efficacy. For instance, in August 2024, Lupin Ltd., an India-based pharmaceutical company, launched Doxorubicin Hydrochloride Liposome Injection in two formulations: 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL). As of June 2024, this injection had an estimated annual sales figure of approximately USD 40.9 million in the U.S. market. This positions Lupin strategically within the oncology segment, expanding its portfolio to include this significant cancer treatment option. Lupin's commitment to enhancing patient health outcomes is reflected in this launch, as it aims to provide effective treatment alternatives in a competitive pharmaceutical landscape.

Major companies operating in the liposomal drug delivery devices market include Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., CSPC Pharmaceutical Group Limited, Ipsen SA, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd., Nanomerics Ltd., Luye Pharma Group Ltd., Leadiant Biosciences Inc., Pacira Biosciences Inc., Nippon Kayaku Co. Ltd., Celsion Corporation, Acrotech Biopharma Inc., Aphios Pharma LLC, CytImmune Sciences Inc., NanoSphere Health Sciences Inc., Cel-Sci Corporation, Lipoid GmbH, Liposome Company Inc., Liposome Research Days Corporation, Taiwan Liposome Company, T&T Scientific Corporation

North America was the largest region in the liposomal drug delivery devices market in 2024. Asia-Pacific was the second-largest region in the global liposomal drug delivery devices market share. The regions covered in the liposomal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liposomal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The liposomal drug delivery devices market consists of sales of instruments such as liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liposomal Drug Delivery Devices Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liposomal drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for liposomal drug delivery devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liposomal drug delivery devices market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Liposomal Drug Delivery Devices Market Characteristics

3. Liposomal Drug Delivery Devices Market Trends And Strategies

4. Liposomal Drug Delivery Devices Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Liposomal Drug Delivery Devices Growth Analysis And Strategic Analysis Framework

6. Liposomal Drug Delivery Devices Market Segmentation

7. Liposomal Drug Delivery Devices Market Regional And Country Analysis

8. Asia-Pacific Liposomal Drug Delivery Devices Market

9. China Liposomal Drug Delivery Devices Market

10. India Liposomal Drug Delivery Devices Market

11. Japan Liposomal Drug Delivery Devices Market

12. Australia Liposomal Drug Delivery Devices Market

13. Indonesia Liposomal Drug Delivery Devices Market

14. South Korea Liposomal Drug Delivery Devices Market

15. Western Europe Liposomal Drug Delivery Devices Market

16. UK Liposomal Drug Delivery Devices Market

17. Germany Liposomal Drug Delivery Devices Market

18. France Liposomal Drug Delivery Devices Market

19. Italy Liposomal Drug Delivery Devices Market

20. Spain Liposomal Drug Delivery Devices Market

21. Eastern Europe Liposomal Drug Delivery Devices Market

22. Russia Liposomal Drug Delivery Devices Market

23. North America Liposomal Drug Delivery Devices Market

24. USA Liposomal Drug Delivery Devices Market

25. Canada Liposomal Drug Delivery Devices Market

26. South America Liposomal Drug Delivery Devices Market

27. Brazil Liposomal Drug Delivery Devices Market

28. Middle East Liposomal Drug Delivery Devices Market

29. Africa Liposomal Drug Delivery Devices Market

30. Liposomal Drug Delivery Devices Market Competitive Landscape And Company Profiles

31. Liposomal Drug Delivery Devices Market Other Major And Innovative Companies

32. Global Liposomal Drug Delivery Devices Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liposomal Drug Delivery Devices Market

34. Recent Developments In The Liposomal Drug Delivery Devices Market

35. Liposomal Drug Delivery Devices Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기